| Edvin Dilanchiyan, MD | |
|
1310 W Stewart Dr Ste 410, Orange, CA 92868-3855 | |
| (714) 639-9401 | |
| Not Available |
| Full Name | Edvin Dilanchiyan |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 22 Years |
| Location | 1310 W Stewart Dr Ste 410, Orange, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245483700 | NPI | - | NPPES |
| 1912919804 | Other | CA | TYPE 2 NPI |
| A126746 | Other | CA | MEDICAL LICENSE NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | A126746 (California) | Primary |
| 207R00000X | Internal Medicine | A126746 (California) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pride Hospice Care, Inc | Burbank, CA | Hospice |
| Glendale Adventist Medical Center | Glendale, CA | Hospital |
| California Hospital Medical Center La | Los angeles, CA | Hospital |
| Glendale Adventist Medical Center Dp/snf | Glendale, CA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hospitalist Group Of Montebello Inc | 2264715143 | 27 |
| Galen Inpatient Physicians Pc | 3678464633 | 345 |
News Archive
Precision Therapeutics announces the acceptance of a new abstract on the ChemoFx® in vitro drug response marker for publication in conjunction with the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.
In a proof-of-concept study with mice, scientists at The Johns Hopkins University show that a novel coating they made with antibiotic-releasing nanofibers has the potential to better prevent at least some serious bacterial infections related to total joint replacement surgery.
Many anesthesia residents are carrying high educational debt—$150,000 or higher—that may constrain their employment decisions after graduation, according to a survey study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.
Among rescue and recovery workers exposed to the dust, debris, and fumes following the World Trade Center terrorist attack, there was an increased incidence of prostate and thyroid cancers and multiple myeloma, although it is not clear how big a factor medical screening and non-WTC risk factors contributed to these increases, according to a study in the December 19 issue of JAMA.
› Verified 2 days ago
| Entity Name | Galen Inpatient Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689320459 PECOS PAC ID: 3678464633 Enrollment ID: O20040322000680 |
News Archive
Precision Therapeutics announces the acceptance of a new abstract on the ChemoFx® in vitro drug response marker for publication in conjunction with the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.
In a proof-of-concept study with mice, scientists at The Johns Hopkins University show that a novel coating they made with antibiotic-releasing nanofibers has the potential to better prevent at least some serious bacterial infections related to total joint replacement surgery.
Many anesthesia residents are carrying high educational debt—$150,000 or higher—that may constrain their employment decisions after graduation, according to a survey study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.
Among rescue and recovery workers exposed to the dust, debris, and fumes following the World Trade Center terrorist attack, there was an increased incidence of prostate and thyroid cancers and multiple myeloma, although it is not clear how big a factor medical screening and non-WTC risk factors contributed to these increases, according to a study in the December 19 issue of JAMA.
› Verified 2 days ago
| Entity Name | Hospitalist Medicine Physicians Of California Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184663965 PECOS PAC ID: 8426062027 Enrollment ID: O20060202000956 |
News Archive
Precision Therapeutics announces the acceptance of a new abstract on the ChemoFx® in vitro drug response marker for publication in conjunction with the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.
In a proof-of-concept study with mice, scientists at The Johns Hopkins University show that a novel coating they made with antibiotic-releasing nanofibers has the potential to better prevent at least some serious bacterial infections related to total joint replacement surgery.
Many anesthesia residents are carrying high educational debt—$150,000 or higher—that may constrain their employment decisions after graduation, according to a survey study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.
Among rescue and recovery workers exposed to the dust, debris, and fumes following the World Trade Center terrorist attack, there was an increased incidence of prostate and thyroid cancers and multiple myeloma, although it is not clear how big a factor medical screening and non-WTC risk factors contributed to these increases, according to a study in the December 19 issue of JAMA.
› Verified 2 days ago
| Entity Name | Jonathan Nasseri Md Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194063529 PECOS PAC ID: 8921253469 Enrollment ID: O20130306000489 |
News Archive
Precision Therapeutics announces the acceptance of a new abstract on the ChemoFx® in vitro drug response marker for publication in conjunction with the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.
In a proof-of-concept study with mice, scientists at The Johns Hopkins University show that a novel coating they made with antibiotic-releasing nanofibers has the potential to better prevent at least some serious bacterial infections related to total joint replacement surgery.
Many anesthesia residents are carrying high educational debt—$150,000 or higher—that may constrain their employment decisions after graduation, according to a survey study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.
Among rescue and recovery workers exposed to the dust, debris, and fumes following the World Trade Center terrorist attack, there was an increased incidence of prostate and thyroid cancers and multiple myeloma, although it is not clear how big a factor medical screening and non-WTC risk factors contributed to these increases, according to a study in the December 19 issue of JAMA.
› Verified 2 days ago
| Entity Name | Hospitalist Group Of Montebello Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578959318 PECOS PAC ID: 2264715143 Enrollment ID: O20170220002677 |
News Archive
Precision Therapeutics announces the acceptance of a new abstract on the ChemoFx® in vitro drug response marker for publication in conjunction with the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.
In a proof-of-concept study with mice, scientists at The Johns Hopkins University show that a novel coating they made with antibiotic-releasing nanofibers has the potential to better prevent at least some serious bacterial infections related to total joint replacement surgery.
Many anesthesia residents are carrying high educational debt—$150,000 or higher—that may constrain their employment decisions after graduation, according to a survey study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.
Among rescue and recovery workers exposed to the dust, debris, and fumes following the World Trade Center terrorist attack, there was an increased incidence of prostate and thyroid cancers and multiple myeloma, although it is not clear how big a factor medical screening and non-WTC risk factors contributed to these increases, according to a study in the December 19 issue of JAMA.
› Verified 2 days ago
| Entity Name | Glendale Hospitalist Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427565506 PECOS PAC ID: 8729348289 Enrollment ID: O20180201002916 |
News Archive
Precision Therapeutics announces the acceptance of a new abstract on the ChemoFx® in vitro drug response marker for publication in conjunction with the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.
In a proof-of-concept study with mice, scientists at The Johns Hopkins University show that a novel coating they made with antibiotic-releasing nanofibers has the potential to better prevent at least some serious bacterial infections related to total joint replacement surgery.
Many anesthesia residents are carrying high educational debt—$150,000 or higher—that may constrain their employment decisions after graduation, according to a survey study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.
Among rescue and recovery workers exposed to the dust, debris, and fumes following the World Trade Center terrorist attack, there was an increased incidence of prostate and thyroid cancers and multiple myeloma, although it is not clear how big a factor medical screening and non-WTC risk factors contributed to these increases, according to a study in the December 19 issue of JAMA.
› Verified 2 days ago
| Entity Name | Ca Hospital Hospitalist Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114483146 PECOS PAC ID: 8527309442 Enrollment ID: O20190402002768 |
News Archive
Precision Therapeutics announces the acceptance of a new abstract on the ChemoFx® in vitro drug response marker for publication in conjunction with the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.
In a proof-of-concept study with mice, scientists at The Johns Hopkins University show that a novel coating they made with antibiotic-releasing nanofibers has the potential to better prevent at least some serious bacterial infections related to total joint replacement surgery.
Many anesthesia residents are carrying high educational debt—$150,000 or higher—that may constrain their employment decisions after graduation, according to a survey study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.
Among rescue and recovery workers exposed to the dust, debris, and fumes following the World Trade Center terrorist attack, there was an increased incidence of prostate and thyroid cancers and multiple myeloma, although it is not clear how big a factor medical screening and non-WTC risk factors contributed to these increases, according to a study in the December 19 issue of JAMA.
› Verified 2 days ago
| Entity Name | Edvin Dilanchiyan Md Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447726849 PECOS PAC ID: 3971844556 Enrollment ID: O20190409000226 |
News Archive
Precision Therapeutics announces the acceptance of a new abstract on the ChemoFx® in vitro drug response marker for publication in conjunction with the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.
In a proof-of-concept study with mice, scientists at The Johns Hopkins University show that a novel coating they made with antibiotic-releasing nanofibers has the potential to better prevent at least some serious bacterial infections related to total joint replacement surgery.
Many anesthesia residents are carrying high educational debt—$150,000 or higher—that may constrain their employment decisions after graduation, according to a survey study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.
Among rescue and recovery workers exposed to the dust, debris, and fumes following the World Trade Center terrorist attack, there was an increased incidence of prostate and thyroid cancers and multiple myeloma, although it is not clear how big a factor medical screening and non-WTC risk factors contributed to these increases, according to a study in the December 19 issue of JAMA.
› Verified 2 days ago
| Entity Name | Careconnectmd Ca Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366063125 PECOS PAC ID: 5496178055 Enrollment ID: O20200715000596 |
News Archive
Precision Therapeutics announces the acceptance of a new abstract on the ChemoFx® in vitro drug response marker for publication in conjunction with the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.
In a proof-of-concept study with mice, scientists at The Johns Hopkins University show that a novel coating they made with antibiotic-releasing nanofibers has the potential to better prevent at least some serious bacterial infections related to total joint replacement surgery.
Many anesthesia residents are carrying high educational debt—$150,000 or higher—that may constrain their employment decisions after graduation, according to a survey study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.
Among rescue and recovery workers exposed to the dust, debris, and fumes following the World Trade Center terrorist attack, there was an increased incidence of prostate and thyroid cancers and multiple myeloma, although it is not clear how big a factor medical screening and non-WTC risk factors contributed to these increases, according to a study in the December 19 issue of JAMA.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Edvin Dilanchiyan, MD 1934 Calle Sirena, Glendale, CA 91208-3033 Ph: (818) 823-0347 | Edvin Dilanchiyan, MD 1310 W Stewart Dr Ste 410, Orange, CA 92868-3855 Ph: (714) 639-9401 |
News Archive
Precision Therapeutics announces the acceptance of a new abstract on the ChemoFx® in vitro drug response marker for publication in conjunction with the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.
In a proof-of-concept study with mice, scientists at The Johns Hopkins University show that a novel coating they made with antibiotic-releasing nanofibers has the potential to better prevent at least some serious bacterial infections related to total joint replacement surgery.
Many anesthesia residents are carrying high educational debt—$150,000 or higher—that may constrain their employment decisions after graduation, according to a survey study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.
Among rescue and recovery workers exposed to the dust, debris, and fumes following the World Trade Center terrorist attack, there was an increased incidence of prostate and thyroid cancers and multiple myeloma, although it is not clear how big a factor medical screening and non-WTC risk factors contributed to these increases, according to a study in the December 19 issue of JAMA.
› Verified 2 days ago
Dr. James W Roh, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2501 E Chapman Ave, Orange, CA 92869 Phone: 714-639-9401 Fax: 714-639-7095 | |
Andy T Tran, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-880-7812 | |
Anwar Abdelhadi, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2501 E Chapman Ave, Orange, CA 92869 Phone: 714-771-8000 | |
Amish Dangodara, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: Uci Medical Center, 101 The City Drive South, Orange, CA 92868 Phone: 714-456-8978 | |
Dr. Ani Bussel, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-880-7812 | |
Dr. Andrea D. Avery, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-880-7812 | |
Kang Hsu, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 1310 W Stewart Dr, Suite 410, Orange, CA 92868 Phone: 714-639-9401 Fax: 714-639-7095 |